Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K31/00 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/175857COMPOUNDS FOR USE IN INFLAMMATORY CONDITIONS
WO 10.09.2021
Int.Class A61K 38/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
12Cyclic peptides
Appl.No PCT/EP2021/055187 Applicant PHARMA MAR, S.A. Inventor AVILÉS MARÍN, Pablo
The present invention relates to the use of compounds in the treatment of inflammation, preferably inflammation associated with activation of Toll-like receptors. The invention also relates to the use of compounds to treat pathogen-induced inflammation.
2.WO/2021/254582EFFICACY OF (SOFOSBUVIR PLUS LEDIPASVIR) IN EGYPTIAN PATIENTS WITH COVID-19COMPARED TO STANDARD OF CARE TREATMENT.
WO 23.12.2021
Int.Class A61K 31/439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
439the ring forming part of a bridged ring system, e.g. quinuclidine
Appl.No PCT/EG2020/000013 Applicant ALMAZA MILITARY FEVER HOSPITAL Inventor EL-GOHARY, Mohamed Abdel-Salam
The antivirals ledipasvir is particularly attractive as therapeutics to combat the new corona virus with minimal side effects, commonly fatigue and headache. The drugs (ledipasvir/sofosbuvir) could be very effective owing to their dual inhibitory actions on two viral enzymes. The present study aimed to test and suggest possible inhibitors, DAA drugs, currently in the market stop the infection immediately. Sofosbuvir, ledipasvir can be used against the new strain of coronavirus that emerged with promising results.
3.WO/2021/211792TREATMENT OF CORONAVIRUS INFECTIONS WITH AURANOFIN
WO 21.10.2021
Int.Class A61K 31/7135
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7135Compounds containing heavy metals
Appl.No PCT/US2021/027404 Applicant GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. Inventor KUMAR, Mukesh
The present disclosure provides methods for treating viral infections, in particular treating coronavirus infections in a subject with auranofin.
4.WO/2021/175250COMPOUNDS AND METHODS FOR TREATING DISEASES AND/OR CONDITIONS CAUSED BY CORONAVIRUS
WO 10.09.2021
Int.Class A61K 31/43
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
425Thiazoles
429condensed with heterocyclic ring systems
43Compounds containing 4-thia-1-azabicyclo heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
Appl.No PCT/CN2021/078875 Applicant MIOS PHARMACEUTICALS LIMITED Inventor LEE, Wai Yip Thomas
Compounds and compositions, for example vardenafil, for treating diseases and/or conditions caused by, arising from, and/or associated with coronavirus in a subject, for example a subject infected with SARS-CoV-2 or other coronavirus. Combinations of agents useful for treating diseases and/or conditions caused by, arising from, and/or associated with coronavirus in a subject, for example, vardenafil and Remdesivir, are also provided.
5.WO/2023/280828A PHARMACEUTICAL COMPOSITION COMPRISING BAY 86-5277 AND SALTS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTIONS AND HYPERINFLAMMATION
WO 12.01.2023
Int.Class A61K 31/495
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
Appl.No PCT/EP2022/068544 Applicant CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN Inventor LANDMESSER, Ulf
The invention relates to a pharmaceutical composition comprising BAY 86-5277 or salt thereof for use in the treatment and/or prevention of a medical condition associated with a viral infection and comprising hyperinflammation in a human subject. The invention further relates to a combination of BAY 86-5277 or a salt thereof and at least one other treatment, such as a guideline treatment for severe respiratory disease, for example recommended by the S3 guideline on in-patient treatment of COVID-19, preferably a glucocorticoid, more preferably dexamethasone. The invention further relates to a pharmaceutical composition comprising BAY 86-5277 or salt thereof or said combination with a glucocorticoid, and use of the combination or composition, in the treatment and/or prevention of a viral infection in a subject and/or a medical condition associated with hyperinflammation, preferably hyperinflammation in the respiratory tract, acute respiratory failure, pneumonia, acute respiratory distress syndrome and/or multiorgan failure. In preferred embodiments, the invention relates to the treatment and/or prevention of a medical condition associated with a SARS-CoV infection, preferably SARS-CoV-2 infection.
6.WO/2022/061420FORMULATIONS COMPRISING BOTANICAL EXTRACTS
WO 31.03.2022
Int.Class A61K 31/365
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
Appl.No PCT/AU2021/051126 Applicant APEX BIOTECH RESEARCH PTY LTD Inventor XIAO, Zhicheng
The invention relates generally to combinations and compositions comprising botanical extracts useful in the treatment or prevention of viral and bacterial infections. In particular, the invention relates to combinations and compositions comprising two or more compounds selected from andrographolide or a derivative, or pharmaceutically acceptable salt thereof, ursolic acid, or a pharmaceutically acceptable salt thereof, and piceid or a derivative, or pharmaceutically acceptable salt thereof and use of the combinations and compositions in the treatment or prevention of viral and bacterial infections.
7.WO/2022/261069METHODS AND TREATMENT OF VIRAL INFECTION WITH SUBSTITUTED PYRAZOLO-PYRIMIDINES
WO 15.12.2022
Int.Class A61K 31/519
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
Appl.No PCT/US2022/032465 Applicant VERGE ANALYTICS, INC. Inventor RHODES, Jane
The present disclosure provides compounds that are useful for the treatment of certain coronavirus infections.
8.WO/2021/255218A PHARMACEUTICAL COMBINATION COMPRISING AN ANTI-VIRAL PROTONOPHORE AND A SERINE PROTEASE INHIBITOR
WO 23.12.2021
Int.Class A61K 31/609
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
60Salicylic acid; Derivatives thereof
609Amides, e.g. salicylamide
Appl.No PCT/EP2021/066543 Applicant CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN Inventor WITZENRATH, Martin
The invention relates to a pharmaceutical combination, comprising a therapeutically effective amount of an anti-viral protonophore, and a therapeutically effective amount of a serine protease inhibitor. In preferred embodiments the invention relates to a combination of niclosamide and camostat mesylate. The invention further relates to a pharmaceutical composition comprising the combination, and use of the combination or composition in a treatment and/or prevention of a viral infection in a subject and/or a medical condition associated with a viral infection. In preferred embodiments the invention relates to the treatment and/or prevention of a SARS-CoV virus, preferably SARS-CoV-2.
9.20220233564OPHTHALMOLOGICAL FORMULATIONS FOR THE PREVENTION OF A CORONAVIRUS INFECTION
US 28.07.2022
Int.Class A61K 31/706
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
Appl.No 17583781 Applicant UNIVERSITY OF SOUTH FLORIDA Inventor Vijaykumar Sutariya

The present disclosure provides for an ophthalmological composition comprising remdesivir and an ophthalmologically suitable carrier, and the use thereof for treating and preventing a coronavirus infection and treating conjunctivitis.

10.20220249654NUCLEIC ACID BASED COMBINATION VACCINES
US 11.08.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17665808 Applicant CureVac AG Inventor Cornelia OOSTVOGELS

The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). The invention is also directed to first and second and further medical uses of the pharmaceutical compositions and combination vaccines, and to methods of treating or preventing a Coronavirus infection and a further virus infection.